Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIp Group Regulatory News (IPO)

Share Price Information for Ip Group (IPO)

Share Price is delayed by 15 minutes
Get Live Data
66.20    -1.80 (-2.65%)
Bid:
65.90
Ask:
66.70
Spread: 0.80 (1.214%)
Market Cap: £584.83m
IPO Live PriceLast checked at - London Stock Exchange

Intraday Ip Group Share Chart

Board changes

4 May 2018 07:00

RNS Number : 1008N
IP Group PLC
04 May 2018
 

FOR RELEASE ON

04 May 2018

 

IP Group plc - Board changes

 

IP Group plc (LSE: IPO) ("IP Group" or "the Group" or "the Company"), the developer of intellectual property-based businesses, announces that Mike Humphrey has indicated that for personal reasons he wishes to retire and step down from his position as Non-executive Chairman and a director of the Company as soon as a suitable replacement can be recruited.

 

Mr Humphrey joined the Board of IP Group in October 2011 as a non-executive Director and became Non-executive Chairman in March 2015. He has served as Senior Independent Director, Chairman of the Remuneration Committee and is currently Chairman of the Nomination Committee and a member of the Remuneration Committee.

 

In addition, IP Group announces that Heejae Chae has been appointed as Non-executive Director with immediate effect while Professor Lynn Gladden has indicated that she will be stepping down from her role as Non-executive Director on or prior to 31 December 2018. Professor Gladden has been appointed to the role of Executive Chairman of the Engineering and Physical Sciences Research Council (EPSRC) with effect from 1st of October and, as such, will need to step down from her role at IP Group to avoid any potential conflict of interests.

 

Mr Chae is currently Chief Executive of AIM-listed Scapa Group plc, a global supplier of products for healthcare and industrial markets. Prior to joining Scapa, Mr Chae was Group Chief Executive of Volex Group plc. He was previously the Group General Manager, Radio Frequency Worldwide, for Amphenol Corporation. He spent the early part of his career in finance at The Blackstone Group and Credit Suisse First Boston before moving into industry. Mr Chae has degrees in Economics and Engineering from Columbia University and an MBA from Harvard University. Mr Chae also serves on the Board of Overseers at Boston Children's Hospital and is an Advisory Council Member at Columbia University.

 

Alan Aubrey, Chief Executive of IP Group, said: "Mike has made a significant contribution to the growth of IP Group during his tenure. On behalf of the Board and all of the Company's staff, I would like to thank Mike for his hard work and wise counsel over the years and to wish him well. I would also like to express my thanks to Lynn for her contribution over the last four years and I'm delighted to welcome Heejae Chae to the Board and look forward to working with him."

 

Mike Humphrey, Chairman, said: "Since joining IP Group, the Company has undergone a rapid period of growth which has seen a near ten-fold increase in the value of the portfolio as well as expansion into both the US and Australasia. It has been an honour to work alongside such a talented team and I am confident that the Group will go from strength to strength."

 

A further announcement will be made in due course once Mr Humphrey's replacement has been selected.

 

This announcement is made pursuant to Listing Rule 9.6.11R. There are no other details required to be disclosed under Listing Rule 9.6.13R. There are no further disclosures required under the Disclosure and Transparency Rules.

 

For more information, please contact:

 

IP Group plc

www.ipgroupplc.com

Alan Aubrey, Chief Executive OfficerGreg Smith, Chief Financial OfficerLiz Vaughan-Adams, Communications

+44 (0) 20 7444 0050+44 (0) 20 7444 0062/+44 (0) 7979 853802

Charlotte Street Partners

Andrew Wilson

+44 (0) 7810 636995

Martha Walsh

+44 (0) 7876 245962

 

Notes for editors

 

About IP Group

 

IP Group is a leading intellectual property commercialisation company which focuses on evolving great ideas, mainly from its partner universities, into world-changing businesses. The Group has pioneered a unique approach to developing these ideas and the resulting businesses by providing access to business building expertise, capital (through its 100%-owned FCA-authorised subsidiaries IP Capital and Parkwalk Advisors), networks, recruitment and business support. IP Group has a strong track record of success and its portfolio comprises holdings in early-stage to mature businesses across life sciences and technology. IP Group is listed on the Main Market of the London Stock Exchange under the code IPO.

Group holdings in portfolio companies reflect the undiluted beneficial equity interest excluding debt, unless otherwise explicitly stated.

For more information, please visit our website at www.ipgroupplc.com.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
BOAVXLFBVEFXBBB
Date   Source Headline
26th Mar 202112:26 pmRNSEMA positive opinion for Diurnal's Chronocort
10th Mar 20217:00 amRNSAnnual Results
4th Mar 20216:07 pmRNSHolding(s) in Company
2nd Mar 202112:03 pmRNSHolding(s) in Company
24th Feb 202110:33 amRNSNotice of Results
18th Feb 20214:31 pmRNSHolding(s) in Company
18th Feb 20218:00 amRNSHolding(s) in Company
17th Feb 20217:00 amRNSPortfolio company ApcinteX acquired by Centessa
10th Feb 20217:00 amRNSIP Group, Inc. raises $50.0m (£36.5m*) of funding
9th Feb 20213:52 pmRNSHolding(s) in Company
2nd Feb 20215:15 pmRNSHolding(s) in Company
11th Jan 20215:29 pmRNSHolding(s) in Company
6th Jan 20214:57 pmRNSPortfolio co Hinge Health completes $300m round
6th Jan 202111:34 amRNSHolding(s) in Company
6th Jan 20217:00 amRNSPortfolio co Oxbotica completes £36m funding round
4th Dec 202011:41 amRNSHolding(s) in Company
3rd Dec 20208:01 amRNSArtios and Merck in global strategic collaboration
25th Nov 20207:00 amRNSDirector Declaration
23rd Nov 20205:05 pmRNSHolding(s) in Company
21st Oct 20207:00 amRNSInvestor webinar
13th Oct 20207:00 amRNSOxford Nanopore funding round and contract win
9th Oct 20209:46 amRNSOxford Nanopore's LamPORE test gains CE-IVD mark
7th Oct 20207:00 amRNSEnterprise Therapeutics' program acquired by Roche
23rd Sep 20201:40 pmRNSHolding(s) in Company
15th Sep 202012:07 pmRNSSecond Price Monitoring Extn
15th Sep 202012:02 pmRNSPrice Monitoring Extension
7th Sep 202012:07 pmRNSSecond Price Monitoring Extn
7th Sep 202012:02 pmRNSPrice Monitoring Extension
1st Sep 20205:18 pmRNSForm 8.3 - Modern Water plc
5th Aug 20207:00 amRNSHalf-yearly results
3rd Aug 20207:00 amRNSNanopore partners with govt on covid-19 test
30th Jul 202012:08 pmRNSSecond Price Monitoring Extn
30th Jul 202012:02 pmRNSPrice Monitoring Extension
29th Jul 20209:45 amRNSHolding(s) in Company
28th Jul 20202:44 pmRNSNotice of Results
14th Jul 20201:29 pmRNSIP Group sells 9.16m shares in Ceres Power
14th Jul 20207:00 amRNSResult of secondary placing in Ceres Power
13th Jul 20205:11 pmRNSProposed secondary placing in Ceres Power Holdings
6th Jul 202012:02 pmRNSPrice Monitoring Extension
6th Jul 20207:00 amRNSAppoints Prof. Clark Chair of ESG Ethics Committee
3rd Jul 202012:07 pmRNSSecond Price Monitoring Extn
3rd Jul 202012:02 pmRNSPrice Monitoring Extension
24th Jun 20202:39 pmRNSHolding(s) in Company
24th Jun 20208:10 amRNSHolding(s) in Company
23rd Jun 202011:37 amRNSLTIP & DBSP awards; Director/PDMR shareholding
18th Jun 20202:05 pmRNSResult of AGM
18th Jun 20207:00 amRNSAGM Statement
9th Jun 20205:47 pmRNSAGM update
5th Jun 20206:28 pmRNSHolding(s) in Company
26th May 202010:05 amRNSInivata receives $25m investment from NeoGenomics

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.